Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase

Circulation

Volumn 129, Issue 4, 2014, Pages 451-462

  Belge, Catharina ^a   Hammond, Joanna ^a   Dubois Deruy, Emilie ^a   Manoury, Boris ^a   Hamelet, Julien ^a   Beauloye, Christophe ^a   Markl, Andreas ^a   Pouleur, Anne Catherine ^a   Bertrand, Luc ^a   Esfahani, Hrag ^a   Jnaoui, Karima ^a   Götz, Konrad R ^b   Nikolaev, Viacheslav O ^b   Vanderper, Annelies ^c   Herijgers, Paul ^c   Lobysheva, Irina ^a   Iaccarino, Guido ^d   Hilfiker Kleiner, Denise ^e   Tavernier, Geneviève ^f   Langin, Dominique ^f   Dessy, Chantal ^a   Balligand, Jean Luc ^a   more..

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF SALERNO   (Italy)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f University Hospital of Toulouse   (France)

Author keywords

Catecholamines; Hypertrophy; Nitric oxide; Receptors, adrenergic, beta

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN II; BETA 3 ADRENERGIC RECEPTOR; CAVEOLIN 3; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOPRENALINE; NEUROHORMONE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; GENE EXPRESSION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODYNAMIC PARAMETERS; MALE; MORPHOMETRICS; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; WILD TYPE;

CATECHOLAMINES; HYPERTROPHY; NITRIC OXIDE; RECEPTORS, ADRENERGIC, BETA;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; HEART VENTRICLES; HUMANS; HYPERTROPHY; ISOPROTERENOL; MALE; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; NEUROTRANSMITTER AGENTS; NITRIC OXIDE SYNTHASE; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84893345251     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.004940     Document Type: Article

References (48)

1. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115:500-508
2. Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115:527-537
3. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in Β1-Adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999;96:7059-7064
4. Engelhardt S, Hein L, Dyachenkow V, Kranias EG, Isenberg G, Lohse MJ. Altered calcium handling is critically involved in the cardiotoxic effects of chronic Β-Adrenergic stimulation. Circulation. 2004;109:1154-1160
5. Bristow M. Antiadrenergic therapy of chronic heart failure: Surprises and new opportunities. Circulation. 2003;107:1100-1102
6. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD. Molecular characterization of the human Β 3-Adrenergic receptor. Science. 1989;245:1118-1121
7. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H. Functional Β3-Adrenoceptor in the human heart. J Clin Invest. 1996;98:556-562
8. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of Β(3)-Adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation. 2001;103:1649-1655
9. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le Marec H. The negative inotropic effect of Β3-Adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest. 1998;102:1377-1384
10. Varghese P, Harrison RW, Lofthouse RA, Georgakopoulos D, Berkowitz DE, Hare JM. Β(3)-Adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest. 2000;106:697-703
11. Dinçer UD, Bidasee KR, Güner S, Tay A, Ozçelikay AT, Altan VM. The effect of diabetes on expression of Β1-, Β2-, and Β3-Adrenoreceptors in rat hearts. Diabetes. 2001;50:455-461
12. Moniotte S, Belge C, Sekkali B, Massion PB, Rozec B, Dessy C, Balligand JL. Sepsis is associated with an upregulation of functional Β3 adrenoceptors in the myocardium. Eur J Heart Fail. 2007;9:1163-1171
13. Liggett SB, Freedman NJ, Schwinn DA, Lefkowitz RJ. Structural basis for receptor subtype-specific regulation revealed by a chimeric Β 3/Β 2-Adrenergic receptor. Proc Natl Acad Sci U S A. 1993;90:3665-3669
14. Kohout TA, Takaoka H, McDonald PH, Perry SJ, Mao L, Lefkowitz RJ, Rockman HA. Augmentation of cardiac contractility mediated by the human Β(3)-Adrenergic receptor overexpressed in the hearts of transgenic mice. Circulation. 2001;104:2485-2491
15. Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, Ellis CL, Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Paolocci N, Kass DA, Barouch LA. Cardioprotective effect of Β-3 adrenergic receptor agonism: Role of neuronal nitric oxide synthase. J Am Coll Cardiol. 2012;59:1979-1987
16. Moens AL, Leyton-Mange JS, Niu X, Yang R, Cingolani O, Arkenbout EK, Champion HC, Bedja D, Gabrielson KL, Chen J, Xia Y, Hale AB, Channon KM, Halushka MK, Barker N, Wuyts FL, Kaminski PM, Wolin MS, Kass DA, Barouch LA. Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the Β3-Adrenoreceptor. J Mol Cell Cardiol. 2009;47:576-585
17. Tavernier G, Toumaniantz G, Erfanian M, Heymann MF, Laurent K, Langin D, Gauthier C. Β3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human Β3-Adrenergic receptor. Cardiovasc Res. 2003;59:288-296
18. Zarrinpashneh E, Beauloye C, Ginion A, Pouleur AC, Havaux X, Hue L, Viollet B, Vanoverschelde JL, Bertrand L. AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol. Biochem Biophys Res Commun. 2008;376:677-681
19. Massion PB, Dessy C, Desjardins F, Pelat M, Havaux X, Belge C, Moulin P, Guiot Y, Feron O, Janssens S, Balligand JL. Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates Β-Adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation. 2004;110:2666-2672
20. Lobysheva I, Rath G, Sekkali B, Bouzin C, Feron O, Gallez B, Dessy C, Balligand JL. Moderate caveolin-1 downregulation prevents NADPH oxidase-dependent endothelial nitric oxide synthase uncoupling by angiotensin II in endothelial cells. Arterioscler Thromb Vasc Biol. 2011;31:2098-2105
21. Börner S, Schwede F, Schlipp A, Berisha F, Calebiro D, Lohse MJ, Nikolaev VO. FRET measurements of intracellular cAMP concentrations and cAMP analog permeability in intact cells. Nat Protoc. 2011;6:427-438
22. Van den Bergh A, Vanderper A, Vangheluwe P, Desjardins F, Nevelsteen I, Verreth W, Wuytack F, Holvoet P, Flameng W, Balligand JL, Herijgers P. Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res. 2008;77:371-379
23. Bogoyevitch MA, Clerk A, Sugden PH. Activation of the mitogen-Activated protein kinase cascade by pertussis toxin-sensitive and-insensitive pathways in cultured ventricular cardiomyocytes. Biochem J. 1995;309 (Pt 2):437-443
24. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem. 1996;271:22810-22814
25. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by Β-Adrenergic receptor stimulation and blockade. Circulation. 1998;98:1783-1789
26. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frérart F, Belge C, Jnaoui K, Noirhomme P, Feron O, Balligand JL. Endothelial Β3-Adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation Β-blocker nebivolol. Circulation. 2005;112:1198-1205
27. Hammond J, Balligand JL. Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: From contractility to remodeling. J Mol Cell Cardiol. 2012;52:330-340
28. Rapacciuolo A, Esposito G, Caron K, Mao L, Thomas SA, Rockman HA. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol. 2001;38:876-882
29. Du XJ, Gao XM, Wang B, Jennings GL, Woodcock EA, Dart AM. Agedependent cardiomyopathy and heart failure phenotype in mice overexpressing Β(2)-Adrenergic receptors in the heart. Cardiovasc Res. 2000;48:448-454
30. Mohamed TM, Oceandy D, Zi M, Prehar S, Alatwi N, Wang Y, Shaheen MA, Abou-Leisa R, Schelcher C, Hegab Z, Baudoin F, Emerson M, Mamas M, Di Benedetto G, Zaccolo M, Lei M, Cartwright EJ, Neyses L. Plasma membrane calcium pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility through modulation of a compartmentalized cyclic nucleotide microdomain. J Biol Chem. 2011;286:41520-41529
31. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA. Genetic alterations that inhibit in vivo pressureoverload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 2002;105:85-92
32. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL. Endothelial Β3-Adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation. 2004;110:948-954
33. Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang D, Nakamura T, Takimoto E, Kass DA. Pivotal role of cardiomyocyte TGF-Β signaling in the murine pathological response to sustained pressure overload. J Clin Invest. 2011;121:2301-2312
34. Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M, Jans P, Scherrer-Crosbie M, Picard MH, Szelid Z, Gillijns H, Van de Werf F, Collen D, Bloch KD. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res. 2004;94:1256-1262
35. Idigo WO, Reilly S, Zhang MH, Zhang YH, Jayaram R, Carnicer R, Crabtree MJ, Balligand JL, Casadei B. Regulation of endothelial nitricoxide synthase (NOS) S-glutathionylation by neuronal NOS: Evidence of a functional interaction between myocardial constitutive NOS isoforms. J Biol Chem. 2012;287:43665-43673
36. Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S, Casadei B. nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. Circulation. 2005;112:3729-3737
37. Aragón JP, Condit ME, Bhushan S, Predmore BL, Patel SS, Grinsfelder DB, Gundewar S, Jha S, Calvert JW, Barouch LA, Lavu M, Wright HM, Lefer DJ. Β3-Adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. J Am Coll Cardiol. 2011;58:2683-2691
38. Calvert JW, Condit ME, Aragón JP, Nicholson CK, Moody BF, Hood RL, Sindler AL, Gundewar S, Seals DR, Barouch LA, Lefer DJ. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of Β(3)-Adrenergic receptors and increased nitric oxide signaling: Role of nitrite and nitrosothiols. Circ Res. 2011;108:1448-1458
39. Buys ES, Raher MJ, Blake SL, Neilan TG, Graveline AR, Passeri JJ, Llano M, Perez-Sanz TM, Ichinose F, Janssens S, Zapol WM, Picard MH, Bloch KD, Scherrer-Crosbie M. Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload. Am J Physiol Heart Circ Physiol. 2007;293:H620-H627
40. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol. 2009;53:207-215
41. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD, Janssens SP. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009;119:408-416
42. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest. 2005;115:1221-1231
43. Frantz S, Klaiber M, Baba HA, Oberwinkler H, Völker K, GaΒner B, Bayer B, Abeber M, Schuh K, Feil R, Hofmann F, Kuhn M. Stressdependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur Heart J. 2013;34:1233-1244
44. Blanton RM, Takimoto E, Lane AM, Aronovitz M, Piotrowski R, Karas RH, Kass DA, Mendelsohn ME. Protein kinase G I-α inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc. 2012;1:e003731
45. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002;99:11363-11368
46. Fonarow GC. A review of evidence-based Β-blockers in special populations with heart failure. Rev Cardiovasc Med. 2008;9:84-95
47. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-225
48. Sorrentino SA, Doerries C, Manes C, Speer T, Dessy C, Lobysheva I, Mohmand W, Akbar R, Bahlmann F, Besler C, Schaefer A, Hilfiker-Kleiner D, Lüscher TF, Balligand JL, Drexler H, Landmesser U. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional Β1-blockade. J Am Coll Cardiol. 2011;57:601-611